Back to results
US 2026/0272907 A1Published application
Therapeutic Tyrosine Kinase Inhibitors for Multiple Sclerosis
AssigneePrincipia Biopharma Inc.
InventorSana Syed
Life of this patent
Estimating the term…
Abstract
This disclosure relates to the field of therapeutic tyrosine kinase inhibitors, in particular Bruton tyrosine kinase (“BTK”) inhibitors for treatment of subjects with relapsing multiple sclerosis.
Claims18
-30. (canceled)
A method of treating relapsing multiple sclerosis (RMS), comprising the steps of:
- (a) administering a therapeutically effective amount of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-1H-imidazo[4,5-c]pyridin-2(3H)-one (Compound) to a patient in need thereof;
- (b) determining the levels of alanine aminotransferase (ALT) and total bilirubin in the patient;
- (c) continuing to administer the Compound to the patient if the patient's level of ALT is <3×ULN or ceasing administration of the Compound to the patient if the patient has a level of ALT >3×ULN and a level of total bilirubin >2×ULN;
- (d) monitoring the level of ALT in the patient;
- and
- (e) optionally resuming administration of a therapeutically effective amount of the Compound to the patient when the patient's level of ALT is determined to be <1.5×ULN.
3 more elements
(canceled)
-37. (canceled)
A method of treating relapsing multiple sclerosis (RMS), comprising the steps of:
- (a) administering a therapeutically effective amount of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-1H-imidazo[4,5-c]pyridin-2(3H)-one (Compound) to a patient in need thereof;
- (b) determining the level of alanine aminotransferase (ALT) in the patient;
- (c) continuing to administer the Compound to the patient if the patient's level of ALT is <3×ULN or ceasing administration of the Compound to the patient if the patient has a level of ALT of >5×upper limit of normal (ULN);
- (d) monitoring the level of ALT in the patient;
- and
- (e) optionally resuming administration of a therapeutically effective amount of the Compound to the patient when the patient's level of ALT is determined to be <1.5×ULN.
3 more elements
A method of treating relapsing multiple sclerosis (RMS), comprising the steps of:
- (a) administering a therapeutically effective amount of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-1H-imidazo[4,5-c]pyridin-2(3H)-one (Compound) to a patient in need thereof;
- (b) determining the level of alanine aminotransferase (ALT) in the patient;
- (c) continuing to administer the Compound to the patient if the patient's level of ALT is ≤3×ULN or ceasing administration of the Compound to the patient if the patient has a level of ALT >3×ULN and the patient experiences one or more of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and eosinophilia >5%;
- (d) monitoring the level of ALT in the patient;
- and
- (e) optionally resuming administration of a therapeutically effective amount of the Compound to the patient when the patient's level of ALT is determined to be ≤1.5×ULN.
3 more elements
Dependencies are inferred from the claim text.